Global Next-generation Sequencing Market 2026 – 2035

The global Next-Generation Sequencing (NGS) market is expected to grow at a compound annual growth rate of 13.54% from USD 13.70 billion in 2026 to USD 43.18 billion in 2035. In 2025, North America is estimated to make up around 45.1% of the global market, with the region's genomics research ecosystem and significant investment in precision medicine and high penetration of sequencing technologies in clinical diagnostics, oncology, reproductive health, and infectious disease surveillance.

Leading sequencing technology companies, world-class academic and research institutions, established biopharmaceutical firms and strong government funding for genomics and personalized medicine initiatives are present in the region. The increasing use of next-generation sequencing in routine clinical diagnostics, the growing demand for companion diagnostics, the increasing use of genomic data for detection of rare diseases and the increasing use of genomic data in drug discovery continue to drive market growth.

In addition, the rapid evolution of high-throughput sequencing technologies, bioinformatics tools, AI-powered genomic analysis, and strategic partnerships between healthcare institutions, biotech firms, and research laboratories in North America further positions the region as a leader in the global Next-Generation Sequencing (NGS) market.

Market Highlight

• In 2025, the Consumables segment accounted for approximately 56.84% of the global Next-Generation Sequencing (NGS) market, driven by the recurring demand for sequencing reagents, library preparation kits, flow cells, sample preparation kits, and other consumables required across research, clinical diagnostics, oncology, and population genomics applications.

• Sequencing by Synthesis (SBS) represented nearly 61.27% of the technology segment, owing to its superior sequencing accuracy, high throughput, scalability, and cost efficiency, making it the preferred technology for whole-genome sequencing, exome sequencing, RNA sequencing, targeted sequencing, and clinical diagnostics.

• The Oncology segment accounted for approximately 33.69% of the application segment, supported by the increasing adoption of genomic profiling for cancer diagnosis, biomarker discovery, companion diagnostics, precision medicine, and targeted therapy development, alongside the growing global burden of cancer.

• North America dominated the global Next-Generation Sequencing (NGS) market in 2025, driven by its advanced genomics research ecosystem, strong presence of leading sequencing technology providers, extensive precision medicine initiatives, robust government funding, and widespread adoption of NGS across clinical diagnostics, pharmaceutical research, and biotechnology applications.

Significant Growth Factors

Growing Adoption of Precision Medicine and Genomic Diagnostics

Next-generation sequencing technologies are significant contributors to the growth of the precision medicine market in clinical diagnostics, as well as in biomedical research. The use of NGS for disease-causing genetic variants, for targeted therapies and for personalized treatment strategies for oncology, rare genetic diseases, cardiovascular diseases and inherited diseases is becoming more and more common.

The recent drop in the price of sequencing, the speed of sequencing, and its accuracy have made genomic testing more widely used in the clinical setting. Moreover, a surge in national genome sequencing programs and personalized healthcare initiatives are driving market growth globally.

Expanding Applications in Drug Discovery, Infectious Disease Surveillance, and Multi-Omics Research

The Next-Generation Sequencing market is poised to experience significant growth opportunities due to the considerable advancements in sequencing technologies, bioinformatics and multi-omics research. Increasingly, pharmaceutical and biotechnology firms are turning to NGS to identify biomarkers, develop companion diagnostics, stratify patients for clinical trials and find genomic targets to increase the success rate of drug development.

At the same time, health care systems are increasingly relying on NGS to identify pathogens, monitor antimicrobial resistance, conduct outbreak surveillance, and public health genomics. The adoption of NGS is continuing to grow in both research and clinical applications through continuous innovation in long-read sequencing, single-cell sequencing, AI-powered genomic analysis and cloud-based bioinformatics platforms.

Drivers Impact Analysis

Restraints Impact Analysis

What are the Major Advances Changing the Next-generation Sequencing Market Today

High-Throughput Sequencing Platforms and Long-Read Technologies Advancing Genomic Analysis

Sequencing technologies are undergoing continuous innovation, which is transforming the Next-Generation Sequencing (NGS) market by providing high throughput, high accuracy and rapid turnaround. Improvements in long-read sequencing, paired-end sequencing, and ultra-high throughput platforms allow for more precise analysis of complex genome structure and variants, repetitive DNA regions, and epigenetic modifications than ever before possible with traditional techniques.

Applications in cancer genomics, rare disease diagnostics, reproductive health, agricultural genomics and population-sequencing are some of the areas seeing fast-paced development of these technologies. Advances in automation and sequencing cost reduction are also driving the broad use of NGS in research laboratories and clinical diagnostics. Plus, automation and sequencing cost reduction are driving even more access to NGS for research and clinical laboratories.

Artificial Intelligence, Cloud Bioinformatics, and Multi-Omics Integration Enhancing Genomic Interpretation

The paradigm of what can be achieved with analysis and interpretation of genomic data and information is changing quickly with the advent of artificial intelligence (AI), machine learning, and cloud-based bioinformatics platforms. Integrated bioinformatics pipelines process genomics, transcriptomics, proteomics and metabolomics data to provide a holistic understanding of a biological system for diagnosis of disease, biomarker identification and precision medicine.

Automated variant calling, annotation and predictive analytics cuts analysis time dramatically and increases diagnostic accuracy, thanks to the power of AI. New technologies that use cloud to share and collaborate on genomic data are helping healthcare organizations, pharmaceutical firms and research institutions manage and analyze vast amounts of genomic data efficiently.

Single-Cell Sequencing, Spatial Genomics, and Clinical Applications Expanding Precision Medicine

Single cell sequencing, spatial transcriptomics and sophisticated molecular profiling are leading the way in the redefinition of the capabilities of next generation sequencing in clinical and translational research. Single-cell sequencing helps identify the heterogeneity of cells, as well as how they respond to external factors, including immune responses and tumor environments, thereby allowing targeted therapy and personalised treatment.

Spatial genomics maintains tissue architecture and simultaneously maps gene expression in the context of the disease, thereby offering more insight into disease development and drug response. These advances, along with growing clinical use in oncology, infectious disease surveillance, prenatal testing and the diagnosis of rare disease, are driving the spread of NGS into the mainstream of healthcare and precision medicine.

Category Wise Insights

By Product

Why Do Consumables Lead the Market?

The largest product category in the global Next-Generation Sequencing (NGS) market was the Consumables segment, which was valued at around 56.84% of the market for 2025, as the demand for the various components of next-generation sequencing (NGS) runs is a recurring one—such as sequencing reagents, library preparation kits, sample preparation kits, flow cells, chips, and cartridges. Laboratories need to be continually ordering consumables as genomic research, clinical diagnostics, oncology testing, population scale sequencing, and more continues to grow, creating a steady stream of revenue. The continuous development of reagent chemistry, automation-friendly kits, and high throughput workflows add to the strength of the Consumables segment.

By Technology

Why Does Sequencing by Synthesis (SBS) Lead the Market?

In 2025, the Sequencing by Synthesis (SBS) segment accounted for around 61.27% of the technology market, driven by its high sequencing accuracy, scalability, cost-effectiveness, and versatility in research and clinical applications. The high throughput and high accuracy of SBS technology make it widely applicable to whole genome sequencing, targeted sequencing, exome sequencing, RNA sequencing and clinical diagnostics. As sequencing speed, throughput, and workflow automation further improve and more hospitals, research institutes, and pharmaceutical companies are adopting the technology, the leadership of SBS technology is further strengthened.

By Application

Why Does Oncology Lead the Market?

The Oncology segment is expected to represent about 33.69% of the global Next-Generation Sequencing (NGS) market in 2025 and will benefit from the growing application of genomic profiling in cancer diagnosis, biomarker discovery, companion diagnostics, treatment selection, and precision oncology. Personalized treatment strategies and enhanced patient outcomes can be achieved through comprehensive analysis of tumor mutations, gene fusions, copy number variations, and other genomic alterations, which is facilitated by NGS. The Oncology application segment remains the dominant application segment as the incidence of cancer continues to rise worldwide, and the use of liquid biopsy technologies, the availability of targeted therapies and the implementation of precision medicine continues to grow.

Report Scope

Regional Analysis

How Big is the North America Market Size?

North America Next-generation sequencing market size is forecast to reach USD 5.47 billion by 2025 and is expected to reach around USD 17.85 billion by 2035 with a CAGR of 12.55% from 2026 to 2035.

Why Did North America Dominate the Next-Generation Sequencing Market in 2025?

The global NGS market is expected to be dominated by North America in 2025, due to its well-established genomics research environment, high level of precision medicine adoption, and presence of the leading players in the sequencing technology sector. The United States is a leader on the regional market with its large investments in genomic medicine, oncology research, clinical diagnostics, and large-scale population sequencing programs.

This area also hosts academia of excellence, a robust pharmaceutical and biotechnology sector, advanced healthcare facilities and significant government funding for genomics research. Additionally, the ongoing developments in sequencing technologies and the bioinformatics and continuous adoption of NGS in various fields of testing including cancer, rare diseases, reproductive health, and infectious disease surveillance are further highlighting North America's dominance in the global NGS market.

Why is Asia Pacific an Important and Growing Market?

Asia Pacific market is forecast to have the highest compound annual growth rate (CAGR) from 2021 to 2035, owing to the growth of genomic research programs, strengthening investments made by the healthcare industry, and adoption of precision medicine in the region. Countries such as China, Japan, India, South Korea, Singapore, and Australia are investing significantly in their national genome sequencing programs, clinical genomics, and biotechnology innovations.

The market has plenty of opportunities as a result of growing demand for early disease diagnosis, rising prevalence of cancer, growing pharmaceutical R&D and establishment of genomics infrastructure. Furthermore, government investments in personalized medicine, access to advanced sequencing technologies and the progressive growth of local biotechnology companies are driving market growth.

Why is Europe a Strategically Important Market?

Along with its well-established life sciences industry, advanced clinical research, and increasing emphasis on precision healthcare, Europe is also a technologically advanced market for Next-Generation Sequencing. The genomic medicine, translational research and national sequencing programs are on the agenda in countries such as Germany, United Kingdom, France, Italy, Spain, the Netherlands and Switzerland.

Demand for NGS is growing across clinical and research settings due to its increasing use in oncology, in the diagnosis of rare diseases, in reproductive health, and in monitoring infectious diseases. Moreover, their cooperation research programs, positive public funding, and ongoing improvements in bioinformatics and molecular diagnostics give Europe a competitive advantage in the global NGS market.

Why is Latin America Emerging as a Growth Opportunity?

However, Latin America is gradually turning into a promising market, with growing investments in molecular diagnostics, growing genomics research and infrastructure improvement in the healthcare sector. In Brazil, Mexico, Argentina, Chile, and Colombia, genetic testing and precision medicine are being made more available to patients and promoted by partnerships involving healthcare providers, research institutes, and biotechnology firms.

The increasing awareness about hereditary diseases, an increase in cancer screening programs, and the growing demand for advanced diagnostic technologies are all contributing to the adoption of NGS. Also, the region has been expected to offer long-term growth opportunities due to the enhancements which have been made in the capabilities of the laboratories and some government initiatives in the field of healthcare modernization.

Why is the Middle East & Africa an Emerging Market?

The MEA Next-Generation Sequencing market is gaining moderate growth due to the increasing focus of governments on genoming medicine programmes, expanding precision healthcare programmes, and investment in next-generation sequencing infrastructure in the country. Countries such as Saudi Arabia, United Arab Emirates, Qatar, South Africa, and Israel are putting more resources into genomics research, newborn screening, rare disease diagnosis, and cancer genomics.

Market development is supported by the growing incidence of inherited disorders, rising demand for personalised healthcare and expansion of biotechnology research. While adoption is still in its early stages relative to developed markets, continued modernization of healthcare and genomics initiatives promoted by governments are likely to create strong long-term growth.

Key Market Players

• Illumina Inc.

• Thermo Fisher Scientific Inc.

• F. Hoffmann-La Roche Ltd

• QIAGEN N.V.

• Pacific Biosciences of California Inc.

• Oxford Nanopore Technologies plc

• BGI Genomics Co. Ltd.

• Agilent Technologies Inc.

• Revvity Inc. (PerkinElmer)

• Danaher Corporation

• Standard BioTools Inc. (formerly Fluidigm Corporation)

• Eurofins Scientific SE

• Bio-Rad Laboratories Inc.

• Hamilton Company

• Azenta Life Sciences

• 10x Genomics Inc.

• Integrated DNA Technologies (IDT)

• MGI Tech Co. Ltd.

• GENEWIZ (Azenta Life Sciences)

• Novogene Co. Ltd.

• Others

Key Developments

The market has undergone significant developments as producers advance bio-isobutanol commercialization, expand derivative product portfolios, and respond to growing global demand across paints, coatings, and fuel applications.

• June 2026 - Illumina, Inc. has introduced recently developed methods of sequencing and software for the purpose of bioinformatics using AI in order to achieve the availability of sequencing results more accurately, in a quicker manner, and creating new programs of large-scale clinical genomics and population sequencing.

• In April 2026, the revolutionary features of the NGS technologies introduced by Thermo Fisher Scientific Inc. were revealed as automation-enabled workflows for library preparation and corresponding software for genomic data processing to enable laboratories to be more productive in the fields of oncology, infectious disease diagnostics, and personalized medicine.

The Next-generation Sequencing Market is segmented as follows:

By Product

• Sequencing Instruments

• Consumables

• Services

By Technology

• Sequencing by Synthesis (SBS)

• Ion Semiconductor Sequencing

• Single-Molecule Real-Time (SMRT) Sequencing

• Nanopore Sequencing

• Other

By Application

• Oncology

• Clinical Diagnostics

• Reproductive Health

• Infectious Disease Detection

• Rare & Inherited Disease Research

• Drug Discovery & Development

• Agrigenomics & Animal Research

• Others

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America